Windsor Capital Management
ABBV icon

Windsor Capital Management’s AbbVie ABBV Stock Holding History

Windsor Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$841K Buy
3,213
+84
+3% +$21.5K 0.22% 64
2026
Q2 		$788K Buy
3,129
+11
+0.4% +$2.37K 0.2% 66
2026
Q1 		$678K Buy
3,118
+319
+11% +$70.8K 0.19% 71
2025
Q4 		$639K Buy
2,799
+164
+6% +$37.4K 0.18% 75
2025
Q3 		$610K Buy
2,635
+7
+0.3% +$1.42K 0.17% 77
2025
Q2 		$488K Buy
2,628
+9
+0.3% +$1.67K 0.14% 87
2025
Q1 		$549K Buy
2,619
+49
+2% +$9.5K 0.17% 80
2024
Q4 		$457K Buy
2,570
+8
+0.3% +$1.47K 0.14% 89
2024
Q3 		$506K Buy
2,562
+128
+5% +$23.9K 0.15% 86
2024
Q2 		$417K Buy
2,434
+9
+0.4% +$1.49K 0.13% 87
2024
Q1 		$442K Buy
2,425
+116
+5% +$20K 0.14% 85
2023
Q4 		$358K Buy
2,309
+10
+0.4% +$1.46K 0.12% 89
2023
Q3 		$343K Buy
2,299
+8
+0.3% +$1.17K 0.12% 89
2023
Q2 		$309K Buy
2,291
+9
+0.4% +$1.32K 0.1% 90
2023
Q1 		$364K Buy
2,282
+8
+0.4% +$1.22K 0.13% 83
2022
Q4 		$368K Buy
2,274
+577
+34% +$88.5K 0.13% 82
2022
Q3 		$227K Buy
1,697
+8
+0.5% +$1.15K 0.08% 101
2022
Q2 		$258K Buy
1,689
+8
+0.5% +$1.22K 0.09% 102
2022
Q1 		$272K Buy
1,681
+8
+0.5% +$1.16K 0.08% 110
2021
Q4 		$226K Buy
+1,673
New +$198K 0.07% 111
2021
Q3 		– Sell
-2,117
Closed -$238K – 117
2021
Q2 		$238K Buy
2,117
+243
+13% +$27.4K 0.08% 108
2021
Q1 		$202K Sell
1,874
-490
-21% -$52.4K 0.07% 115
2020
Q4 		$253K Buy
2,364
+9
+0.4% +$865 0.09% 104
2020
Q3 		$206K Buy
2,355
+9
+0.4% +$847 0.09% 107
2020
Q2 		$230K Buy
+2,346
New +$207K 0.1% 104
2020
Q1 		– Sell
-2,377
Closed -$210K – 116
2019
Q4 		$210K Buy
+2,377
New +$197K 0.09% 114
2019
Q1 		– Sell
-2,471
Closed -$227K – 117
2018
Q4 		$227K Sell
2,471
-8,292
-77% -$729K 0.12% 106
2018
Q3 		$1.02M Sell
10,763
-359
-3% -$34K 0.46% 55
2018
Q2 		$1.03M Buy
11,122
+565
+5% +$55.2K 0.48% 54
2018
Q1 		$999K Sell
10,557
-1,492
-12% -$164K 0.47% 52
2017
Q4 		$1.16M Sell
12,049
-1,461
-11% -$138K 0.54% 43
2017
Q3 		$979K Hold
13,510
– – 0.49% 43
2017
Q2 		$979K Buy
13,510
+383
+3% +$25.7K 0.49% 43
2017
Q1 		$855K Buy
13,127
+8,822
+205% +$555K 0.44% 46
2016
Q4 		$269K Buy
4,305
+6
+0.1% +$366 0.15% 99
2016
Q3 		$271K Sell
4,299
-8,645
-67% -$560K 0.15% 101
2016
Q2 		$801K Buy
12,944
+360
+3% +$21.9K 0.47% 48
2016
Q1 		$718K Buy
12,584
+3,310
+36% +$184K 0.45% 56
2015
Q4 		$549K Buy
9,274
+622
+7% +$35.8K 0.34% 62
2015
Q3 		$470K Buy
+8,652
New +$563K 0.28% 66
2014
Q1 		– Sell
-1,978
Closed -$104K – 89
2013
Q4 		$104K Buy
1,978
+5
+0.3% +$246 0.06% 118
2013
Q3 		$88K Sell
1,973
-195
-9% -$8.64K 0.05% 125
2013
Q2 		$90K Buy
+2,168
New +$94.8K 0.05% 111

Other funds holding ABBV

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Windsor Capital Management's ABBV Position: Q3 2026 in Review

Windsor Capital Management increased its AbbVie (ABBV) stake by 2.7% in Q3 2026, buying an estimated $21.5K and bringing the position to 3,213 shares worth $841K. The position accounts for 0.22% of the portfolio, ranked #64.

Windsor Capital Management first reported a position in ABBV in Q2 2013 and has held it in 43 quarters since. The position peaked at $1.16M in Q4 2017. 3,064 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Windsor Capital Management held 3,213 shares of AbbVie worth $841K as of Q3 2026.
  • Windsor Capital Management bought 84 AbbVie shares in Q3 2026, an estimated $21.5K.
  • AbbVie made up 0.22% of Windsor Capital Management's portfolio in Q3 2026, its #64 holding.
  • Windsor Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 43 quarters since.
  • Windsor Capital Management's AbbVie position peaked at $1.16M in Q4 2017.
  • 3,064 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Windsor Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.